<DOC>
<DOCNO>EP-0655440</DOCNO> 
<TEXT>
<INVENTION-TITLE>
1-Aminoethylindoles.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3140	A61K3140	A61K31403	A61K31403	A61K31404	A61K314045	A61P100	A61P100	A61P700	A61P702	A61P900	A61P900	A61P912	A61P2500	A61P2500	A61P2506	A61P2518	A61P2520	A61P2524	A61P2526	A61P2528	A61P4300	A61P4300	C07D20900	C07D20904	C07D20908	C07D20924	C07D20930	C07D20936	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P1	A61P1	A61P7	A61P7	A61P9	A61P9	A61P9	A61P25	A61P25	A61P25	A61P25	A61P25	A61P25	A61P25	A61P25	A61P43	A61P43	C07D209	C07D209	C07D209	C07D209	C07D209	C07D209	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to compounds of the formula 
<
IMAGE
>
 wherein R
<
1
>
 to R
<
4
>
 are hydrogen, halogen, lower alkyl, cycloalkyl or trifluoromethyl, R
<
5
>
 and R
<
6
>
 are hydrogen, halogen, lower alkyl, cycloalkyl, trifluoromethyl, hydroxyl or lower alkoxy and R
<
7
>
 is hydrogen or lower alkyl, and pharmaceutically acceptable acid addition salts of the compounds of the formula I. These compounds are particularly suitable for the treatment or prevention of central nervous disorders such as depressions, bipolar disorders, anxiety states, sleep and sexual disorders, psychoses, schizophrenia, migraine and other conditions associated with headache or pain of other types, personality disorders or obsessive-compulsive disorders, social phobia or panic attacks, organic mental disorders, mental disorders in childhood, aggressiveness, age-related memory disorders and behavioural disorders, addiction, obesity, bulimia etc., damage to the central nervous system as a result of trauma, stroke, neurodegenerative disorders etc.; cardiovascular disorders, such as high blood pressure, thrombosis, stroke, and gastrointestinal disorders, such as dysfunction of the motility of the gastrointestinal tract.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
HOFFMANN LA ROCHE
</APPLICANT-NAME>
<APPLICANT-NAME>
F. HOFFMANN-LA ROCHE AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BOES MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
BOES, MICHAEL
</INVENTOR-NAME>
</INVENTORS>
</TEXT>
</DOC>
